Amneal Pharmaceuticals (AMRX) Proxy filing summary

Executive summary

• Achieved 8% revenue growth in 2025, with double-digit growth in Specialty and AvKARE segments, and strong launches in Affordable Medicines and biosimilars.

• Reduced net leverage to 3.5x, refinanced debt to lower interest costs and extend maturities to 2032.

• Expanded R&D pipeline to over 110 programs, advanced collaborations (notably with Metsera/Pfizer), and launched new manufacturing facilities.

• Maintained a mission-driven focus on access to affordable, high-quality medicines and sustainability.

Voting matters and shareholder proposals

• Stockholders will vote to elect 10 directors, approve executive compensation (say-on-pay), and ratify Ernst & Young LLP as independent auditor for 2026.

• Advisory vote on executive compensation and ratification of auditor are both recommended for approval by the Board.

Board of directors and corporate governance

• Board consists of 10 members: 5 Amneal Group Directors and 5 Non-Amneal Group Directors, with an independent Chairman.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, and Conflicts Committees.

• Annual board and management evaluations are conducted, with a focus on diversity and inclusion.

• Amneal Group's voting power dropped below 50% in 2025, ending controlled company status under Nasdaq rules.